Anebulo Pharmaceuticals, Inc. (ANEB) stock
Close on Oct 19, 2026Market cap $28.76KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $28.76K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$7.98M
- EPS, diluted
- -$0.19
- Book value per share
- $0.19
- Diluted shares
- 41M
Trading
- Previous close
- $0.00
- Open
- $0.30
- Day's range
- $0.00 – $0.30
- Volume
- 1,086
- Average volume (20 days)
- 315
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANEB | S&P 500 | Difference | ANEB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -99.8% | +0.6% | −100.4 pts | ||
| 3 months | -99.8% | +3.4% | −103.2 pts | ||
| Year to date | -99.9% | +13.3% | −113.2 pts | ||
| 1 year | -100.0% | +16.6% | −116.6 pts | ||
| 3 years | -100.0% | +86.4% | −186.4 pts | -93.8% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -84.3% | +12.7% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Anebulo Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- News
- Results
About Anebulo Pharmaceuticals
Pharmaceutical Preparations
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, including acute cannabis-induced toxicity in children and acute cannabinoid intoxication in adults. Its lead product candidate, selonabant, is a small molecule antagonist of cannabinoid receptor type-1 designed to rapidly reverse the symptoms of cannabis toxicity and reduce recovery time. The company targets emergency department patients, particularly pediatric cases suffering from accidental ingestion as well as adult cases.
Company profile, executives and historyAnebulo Pharmaceuticals stock: common questions
What is Anebulo Pharmaceuticals's stock price?
ANEB closed at $0.00 on Oct 19, 2026, up 75.00% on the day.
What is Anebulo Pharmaceuticals's market cap?
Anebulo Pharmaceuticals was worth $28.76K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ANEB's P/E ratio?
Anebulo Pharmaceuticals lost money over the twelve months to Dec 31, 2025 (diluted EPS -$0.19), so it has no meaningful P/E ratio.
Does Anebulo Pharmaceuticals pay a dividend?
No. Anebulo Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has ANEB stock performed over the past year?
Including dividends, ANEB returned -100.0% over the past year, against +16.6% for the S&P 500.
Who are Anebulo Pharmaceuticals's competitors?
Companies most similar to Anebulo Pharmaceuticals by business, industry and size include CNBX, PHVS, MIRA, ARTL, CING.
See a number that looks wrong?